NCT02375256View on ClinicalTrials.gov

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2013

Conditions
Tuberculosis
Interventions
BIOLOGICAL

AERAS-402

Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).

BIOLOGICAL

Placebo

Identical buffer solution in which AERAS-402 is formulated.

BIOLOGICAL

BCG (1-8 x105 cfu ID)

BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.

Sponsors

Lead Sponsor

Aeras
All Listed Sponsors
lead

Aeras

OTHER